AFT Pharmaceuticals chair David Flacks told shareholders at today’s annual meeting in Auckland that he expects the company to return to profitability this financial year following years of investment in research and development.
In May, the company announced it had achieved an operating
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
